Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0137 SAD and MAD in Healthy Participants With or Without Elevated Lp(a)
NCT07745114Phase 1Active, not recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAL0137 in elevated lipoprotein(a) (Lp(a)) (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Security Index. Started Jan 2026; status: active, not recruiting.
02
Drugs
SAL0137
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT07745114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745114.